Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Ustekinumab Coverage Policy | OpenPay…
    Ask Trek AI about this page
    CurrentHealthSpringPolicy RX501.114

    Ustekinumab and Associated Biosimilars

    Customize your policy alerts

    Sign up for healthspring Policy RX501.114 alerts

    Get alerted when Policy RX501.114 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of intravenous ustekinumab or an associated biosimilar for Crohn's disease and ulcerative colitis, including age and weight criteria and initial infusion requirements. Self-administered therapy is subject to the applicable pharmacy benefit plan.

    Policy Summary
    PayerHealthSpring
    PolicyUstekinumab and Associated Biosimilars
    Policy CodePolicy RX501.114
    Change TypeNo material change
    Effective DateJul 21, 2026
    Next Review DateNot specified
    Key ActionReview the member's benefit contract or Summary Plan Description along with the written Medical Policy coverage position before making a coverage determination.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered FDA-approved inflammatory bowel disease indications
    8Associated ustekinumab biosimilars listed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Age 2+; 10 kg+Crohn's disease eligibility threshold
    8 weeksInterval before potential subcutaneous dose after initial infusion
    ExperimentalNon-FDA-approved intravenous indications

    Coverage Criteria

    Initial intravenous therapy

    A single intravenous administration may be considered medically necessary when either covered indication group is met.

    Covered indications

    • Crohn's disease: The patient has moderately to severely active Crohn's disease, is 2 years of age or older, and weighs at least 10 kg.Age >= 2 years; weight >= 10 kg

      All Crohn's disease conditions must be met.

    • Ulcerative colitis: The patient is an adult 18 years of age or older with moderately to severely active ulcerative colitis.Age >= 18 years

      Both adult age and disease activity conditions must be met.

    Subcutaneous follow-up therapy

    After the initial intravenous dose, patients may receive a subcutaneous injection 8 weeks later.

    Post-infusion administration: The patient has received the initial intravenous dose for covered Crohn's disease or ulcerative colitis treatment and is scheduled for a possible subcutaneous injection 8 weeks after the first dose.8 weeks after first dose

    No additional continuation criteria are stated in this section.

    Intravenous ustekinumab (Stelara) or an associated biosimilar is considered experimental, investigational, and/or unproven for all other non-FDA-approved indications. Self-administered products are subject to the applicable pharmacy benefit plan.

    Coding and Clinical Measures

    HCPCS CodesHCPCS
    C9399Unclassified drugs or biologicals
    J3357Ustekinumab-related HCPCS code listed by the policy
    J3358Ustekinumab-related HCPCS code listed by the policy
    J3490Unclassified drugs
    J3590Unclassified biologics
    Q5098HCPCS code listed by the policy
    Q5099HCPCS code listed by the policy
    Q5100HCPCS code listed by the policy
    Q5137HCPCS code listed by the policy
    Q5138HCPCS code listed by the policy
    1–10 of 15
    1/2
    Adult Crohn's Disease Activity
    PopulationAdults with moderately to severely active Crohn's disease evaluated in induction trials
    Assessment measureCrohn's Disease Activity Index (CDAI)
    Disease activity thresholdCDAI score 220 to 450
    Crohn's Disease Clinical Remission
    ConditionCrohn's disease clinical remission
    Assessment measureCrohn's Disease Activity Index (CDAI)
    Remission threshold

    Provider Actions

    Note

    Review Benefit Contract

    Review the member's benefit contract or Summary Plan Description when making coverage determinations based on the written Medical Policy. Confirm defined coverage versus noncoverage, benefit exclusions, and limitations such as dollar or duration caps.

    Denial Risk

    Non-FDA-Approved Indications

    Intravenous administration of ustekinumab (Stelara®) or an associated biosimilar is considered experimental, investigational, and/or unproven for all other non-Food and Drug Administration-approved indications.

    Background

    This policy addresses coverage of ustekinumab and associated biosimilars for moderately to severely active Crohn's disease and ulcerative colitis. For covered adult inflammatory bowel disease treatment, the first dose is administered by a healthcare provider through intravenous infusion in a healthcare facility; a subcutaneous injection may follow 8 weeks after the first dose. Self-administered medication is handled under the applicable pharmacy benefit plan, and associated Stelara biosimilars listed by the policy are included within the coverage framework.

    Definitions

    Associated Biosimilars
    Reference medicineStelara (ustekinumab)
    DefinitionMedicines biosimilar to Stelara that are listed as eligible associated biosimilars under the policy
    Listed productsImuldosa, Otulfi, Pyzchiva, and Selarsdi
    Additional listed productsStarjemza, Steqeyma, Wezlana, and Yesintek
    Self-Administered Medication
    AdministrationMedication administered by the patient rather than intravenously by a healthcare provider
    Applicable products

    Initial Therapy Criteria

    Initial intravenous ustekinumab therapy

    A single intravenous administration may be considered medically necessary for one of the covered indications.

    Covered initial therapy indications

    • Crohn's disease criteria: The patient has moderately to severely active Crohn's disease, is 2 years of age or older, and weighs at least 10 kg.Age >= 2 years; weight >= 10 kg

      All listed criteria are required.

    • Ulcerative colitis criteria: The patient has moderately to severely active ulcerative colitis and is an adult 18 years of age or older.Age >= 18 years

      Both adult age and disease activity conditions are required.

    Continuation Criteria

    Subcutaneous dose after initial infusion

    Patients may receive a subcutaneous injection 8 weeks after the first intravenous dose.

    Follow-up dose timing: Following the initial intravenous dose for covered Crohn's disease or ulcerative colitis, a subcutaneous injection may be administered 8 weeks later.8 weeks after first dose

    No additional continuation criteria are stated in this section.

    Ulcerative colitis maintenance trial

    In the UC-2 maintenance trial, subjects who achieved clinical response after induction were randomized to subcutaneous maintenance ustekinumab or placebo.

    UC-2 maintenance regimen: The patient achieved clinical response 8 weeks following intravenous induction and is receiving subcutaneous ustekinumab maintenance at the recommended regimen evaluated in UC-2.90 mg every 8 weeks

    Quantity Limits

    Quantity Limit
    MedicationUstekinumab or an associated biosimilar
    Administration limitA single intravenous administration
    Limit applies perCourse

    Site of Care

    Note

    Administer the first dose in a healthcare facility

    For adults who meet the covered Crohn’s disease or ulcerative colitis criteria, administer the first dose by intravenous infusion in a healthcare facility by a healthcare provider. A subcutaneous injection may then be given 8 weeks after the first dose.

    Associated Biosimilars

    Billing Rule

    Associated biosimilar: Imuldosa

    Imuldosa (ustekinumab-srlf) is listed as an associated biosimilar to Stelara (ustekinumab) under this policy.

    Billing Rule

    Associated biosimilar: Otulfi

    Otulfi (ustekinumab-aauz) is listed as an associated biosimilar to Stelara (ustekinumab) under this policy.

    Billing Rule

    Associated biosimilar: Pyzchiva

    Pyzchiva (ustekinumab-ttwe) is listed as an associated biosimilar to Stelara (ustekinumab) under this policy.

    Policy Summary
    PayerHealthSpring
    PolicyUstekinumab and Associated Biosimilars
    Policy CodePolicy RX501.114
    Change TypeNo material change
    Effective DateJul 21, 2026
    Next Review DateNot specified
    Key ActionReview the member's benefit contract or Summary Plan Description along with the written Medical Policy coverage position before making a coverage determination.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical MeasuresProvider ActionsBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaQuantity LimitsSite of CareAssociated Biosimilars
    CDAI score less than 150
    Pediatric Crohn's Disease Clinical Remission
    ConditionPediatric Crohn's disease clinical remission
    Assessment measurePediatric Crohn's Disease Activity Index (PCDAI)
    Remission thresholdPCDAI score of 10 or less
    Ulcerative Colitis Disease Activity
    ConditionModerately to severely active ulcerative colitis
    Overall disease activityMayo score 6 to 12
    Endoscopy requirementMayo endoscopy subscore at least 2
    Pediatric Crohn's Disease Endoscopic Response
    PopulationPediatric patients with Crohn's disease evaluated at Week 52
    Assessment measureSES-CD score, with baseline SES-CD score at least 3
    Endoscopic responseReduction in SES-CD score greater than 50% or SES-CD score 2 or less
    Mayo Score
    Assessment instrumentComposite Mayo disease activity score
    Score range0 to 12
    Policy-referenced activity rangeMayo score 6 to 12
    Mayo Endoscopy Subscore
    Assessment componentMayo endoscopy subscore
    Subscore rangeEach Mayo subscore is scored from 0 to 3
    Disease activity thresholdMayo endoscopy subscore at least 2
    Clinical Response
    Assessment measureModified Mayo score, defined as the 3-component Mayo score without the Physician's Global Assessment
    Required score changeAt least a 2-point and at least 30% decrease
    Rectal bleeding criterionDecrease from baseline in rectal bleeding subscore by at least 1, or rectal bleeding subscore of 0 or 1
    Histologic Neutrophil Infiltration
    Tissue assessedColon tissue
    Neutrophil criterionNeutrophil infiltration in less than 5% of crypts
    Related mucosal criteriaNo crypt destruction, erosions, ulcerations, or granulation tissue
    Stelara and its associated biosimilars may be self-administered
    Benefit directionRefer self-administered medications to the applicable pharmacy benefit plan
    Clinical Remission in Crohn's Disease
    ConditionCrohn's disease clinical remission
    IndexCrohn's Disease Activity Index (CDAI)
    DefinitionCDAI score less than 150
    Clinical Response in Crohn's Disease
    ConditionCrohn's disease
    Primary response criterionReduction in CDAI score of at least 100 points
    Alternative criterionBeing in clinical remission
    70-Point Response
    Assessment measureCrohn's Disease Activity Index (CDAI)
    Required reductionReduction in CDAI score of at least 70 points
    Response type70-point response
    Pediatric Clinical Remission
    ConditionPediatric Crohn's disease
    Assessment measurePediatric Crohn's Disease Activity Index (PCDAI)
    Remission definitionPCDAI score of 10 or less
    Pediatric Clinical Response
    ConditionPediatric Crohn's disease
    Change from baselineReduction in PCDAI score of more than 12.5 points
    Required total scoreTotal PCDAI score of 30 or less
    Moderately to Severely Active Ulcerative Colitis
    ConditionModerately to severely active ulcerative colitis
    Mayo score6 to 12
    Endoscopy requirementMayo endoscopy subscore at least 2
    Clinical Remission in Ulcerative Colitis
    Stool frequency subscore0 or 1
    Rectal bleeding subscore0, indicating no rectal bleeding
    Mayo endoscopy subscore0 or 1
    Mayo Score
    Score typeComposite disease activity score ranging from 0 to 12
    Component domainsStool frequency, rectal bleeding, centrally reviewed endoscopy, and physician global assessment
    Component scoringEach subscore is scored from 0 (normal) to 3 (most severe)
    Moderately to Severely Active Ulcerative Colitis
    ConditionModerately to severely active ulcerative colitis
    Overall scoreMayo score of 6 to 12
    Endoscopy thresholdMayo endoscopy subscore of at least 2
    Clinical Remission
    Stool frequency subscore0 or 1
    Rectal bleeding subscore0
    Endoscopy subscore0 or 1
    Clinical Response
    Modified Mayo score changeAt least a 2-point and at least 30% decrease
    Rectal bleeding changeDecrease from baseline in rectal bleeding subscore by at least 1, or a rectal bleeding subscore of 0 or 1
    Score compositionModified Mayo score is the 3-component Mayo score without the Physician's Global Assessment
    Endoscopic Improvement
    Assessment componentMayo endoscopy subscore
    Improvement thresholdMayo endoscopy subscore of 0 or 1
    EndpointEndoscopic improvement
    Histologic-Endoscopic Mucosal Improvement
    Endoscopic criterionMayo endoscopy subscore of 0 or 1
    Histologic criterionNeutrophil infiltration in less than 5% of crypts
    Additional tissue criteriaNo crypt destruction, erosions, ulcerations, or granulation tissue

    Ulcerative colitis induction trial

    The UC-1 induction trial evaluated adults with moderately to severely active ulcerative colitis who had failed or inadequately responded to prior therapies.

    UC-1 study population: The patient is an adult with moderately to severely active ulcerative colitis and had an inadequate response to or failed to tolerate a biologic, corticosteroid, and/or 6-MP or AZA therapy.Mayo score 6-12 with endoscopy subscore >= 2

    The trial included subjects who had failed corticosteroids, immunomodulators, or at least one biologic.

    The trial also evaluated 90 mg every 12 weeks as a lower-than-recommended dose; the recommended regimen was evaluated through Week 44.

    Billing Rule

    Associated biosimilar: Selarsdi

    Selarsdi (ustekinumab-aekn) is listed as an associated biosimilar to Stelara (ustekinumab) under this policy.

    Billing Rule

    Associated biosimilar: Starjemza

    Starjemza (ustekinumab-hmny) is listed as an associated biosimilar to Stelara (ustekinumab) under this policy.

    Billing Rule

    Associated biosimilar: Steqeyma

    Steqeyma (ustekinumab-stba) is listed as an associated biosimilar to Stelara (ustekinumab) under this policy.

    Billing Rule

    Associated biosimilar: Wezlana

    Wezlana (ustekinumab-auub) is listed as an associated biosimilar to Stelara (ustekinumab) under this policy.

    Billing Rule

    Associated biosimilar: Yesintek

    Yesintek (ustekinumab-kfce) is listed as an associated biosimilar to Stelara (ustekinumab) under this policy.